Comparative Pharmacology
Head-to-head clinical analysis: ATACAND HCT versus HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATACAND HCT versus HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE.
ATACAND HCT vs HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.
Hydralazine is a direct-acting arteriolar vasodilator that reduces peripheral vascular resistance via relaxation of vascular smooth muscle, possibly by interfering with calcium transport. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, and reducing plasma volume.
One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.
Initially one capsule (25 mg hydralazine/25 mg hydrochlorothiazide, or 50 mg hydralazine/50 mg hydrochlorothiazide) twice daily, increase as needed to a maximum of 200 mg hydralazine/200 mg hydrochlorothiazide daily.
None Documented
None Documented
Candesartan: ~9 hours (terminal). Hydrochlorothiazide: 6-15 hours (terminal, mean ~10 hours).
Hydralazine: 2-8 hours (terminal, prolonged in renal impairment; acetylator phenotype affects clearance; slow acetylators have 2-fold longer half-life). Hydrochlorothiazide: 6-15 hours (terminal, prolonged in renal impairment; clinically relevant for once-daily dosing).
Candesartan: ~33% renal, ~67% biliary/fecal. Hydrochlorothiazide: >95% renal.
Hydralazine: 90% renal (primarily as metabolites, 10-15% unchanged); Hydrochlorothiazide: >95% renal (unchanged). Biliary/fecal: negligible for both.
Category C
Category A/B
Angiotensin II Receptor Blocker / Thiazide Diuretic
Thiazide Diuretic